Rajneesh Nath, MD, medical oncologist at the Banner MD Anderson Cancer Center, discusses early results from the phase 3 SIERRA trial investigating the efficacy of Iomab-B and protocol-specified allogeneic hematopoietic stem cell transplant (alloHCT) in older patients with active, relapsed, or refractory acute myeloid leukemia (AML). Nath explains this study allowed around 80% of patients who did not go into remission to crossover from conventional chemotherapy to the HCT and Iomab-B regimen.

Click here to learn more.